

Make NIPT accessible for all women

Advocate for better health coverage for your patients

Do you want every commercial insurer to cover noninvasive prenatal testing (NIPT) for all your patients—regardless of their risk factors, income, age, or geographic location? Professional societies, including the American Congress of Obstetricians and Gynecologists (ACOG), have recognized NIPT as an option for all pregnant women, regardless of age or risk.¹⁻³

However, many commercial insurance companies do not cover NIPT for all pregnant women. This creates a disparity in the prenatal care services available and could have a serious impact on the level of care they receive.

CAPS has created a simple form to help you easily and automatically send an email to top insurers on your behalf so you can be heard.

To advocate for coverage of NIPT for all your pregnant patients, visit capsprenatal.com/provider-advocacy

About CAPS

The Coalition for Access to Prenatal Screening (CAPS) is a collaborative alliance of six leading genetic testing companies in the U.S. that seeks to improve access to state-of-the-art prenatal screening using cell-free DNA (cfDNA)-based noninvasive prenatal testing (NIPT) that is easily accessible to all pregnant women who choose to pursue aneuploidy screening, regardless of their risk factors, income, age or geographic location. As leading providers of cfDNA-based NIPT, CAPS member companies are working together to promote public awareness about the value of this innovative and highly sensitive screening method and to advocate for the highest standards of quality, service and education.

The CAPS Coalition provides reliable and useful information about cfDNA-based-NIPT to patients, healthcare providers, and public and private insurers.

CAPS will work to encourage appropriate legislative measures and reimbursement coverage policy changes for this medically actionable testing service, which has the potential to improve personalized patient care.

References

1. American College of Obstetricians and Gynecologists. Practice Bulletin No. 163: Screening for fetal aneuploidy. *Obstet Gynecol.* 2016; 127(5):e123-137. doi: 10.1097/AOG.0000000000001439.
2. Benn P, Borrell A, Chiu RW, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. *Prenat Diagn.* 2015;35(8):725-734. doi:10.1002/pd.4608.
3. Gregg AR, Skotko BG, Benkendorf JL, et al. Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. *Genet Med.* 2016;18(10):1056-1065. doi:10.1038/gim.2016.97